Navigation Links
Interleukin Genetics to Present at 2008 BIO International Convention
Date:6/10/2008

Lewis H. Bender to Discuss Factors of Inflammation in Chronic Diseases of

Aging

WALTHAM, Mass., June 10 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), announced today that Lewis H. Bender, Chief Executive Officer, will make a corporate presentation at the BIO Business Forum during the 2008 BIO International Convention in San Diego, CA. The presentation will be held on Wednesday, June 18 at 1:30 PM PDT in room 5A. The presentation will not be webcast. Mr. Bender will be available for one-on-one meetings throughout the conference. For more information, please visit http://www.bio2008.org .

WHO: Lewis H. Bender, Chief Executive Officer of Interleukin Genetics

WHERE: BIO International Convention, San Diego Convention Center, San Diego, CA

WHEN: Wednesday, June 18 at 1:30 PM PDT

WHAT: Long before anyone was using the words "personalized healthcare" and "personalized medicine," Interleukin Genetics was focused on harnessing knowledge about the genetics of a key bodily defense system - inflammation - and developing ways to modulate that system that would promote wellness. Interleukin Genetics will use the BIO Business Forum to discuss the company's proprietary intellectual property, partnering, business model, commercialized genetic tests, and recent milestones.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin, its products and ongoing programs, please visit http://www.ilgenetics.com .

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Announces Management and Board Appointments
2. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
3. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
4. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
5. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
6. Interleukin Genetics Retains Top Life Science Communications Firms
7. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
8. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
9. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
10. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016 Early-career researchers from ... , Uganda and Yemen ... and nutrition   Indonesia , Nepal ... and Yemen are being honored for their accomplishments ... also celebrated for mentoring young women scientists who are pursuing careers in ...
(Date:2/10/2016)... , Feb.10, 2016 ASAE is introducing ... Association Management Companies (AMC) the option of joining or ... annual fee determined by staff size, every employee in ... join ASAE and reap all available member benefits.   ... "Our new organizational membership options will allow organizations of ...
(Date:2/10/2016)... 10, 2016  Allergan plc (NYSE: AGN ) ... Brent Saunders , Allergan,s CEO and President, will be ... session at the RBC Capital Markets Healthcare Conference on ... The New York Palace Hotel in New ... live and can be accessed on Allergan,s Investor Relations ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on ... fill more than 100 tables for its annual event, which will run from ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 3, 2016 ... new market research report "Automated Fingerprint Identification System Market ... Latent Search), Application (Banking & Finance, Government, Healthcare, and ... by MarketsandMarkets, the market is expected to be worth ... of 21.0% between 2015 and 2020. The transformation and ...
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
Breaking Biology News(10 mins):